Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Apatinib Plus FOLFOX-HAIC vs Camrelizumab and Apatinib in HCC With Portal Vein Invasion
NCT05198609Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Started Jan 2022; status: active, not recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05198609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198609.